No profile data available.
Hutchmed (China) Limited (HCM) is a healthcare company in the additional cancer treatment drugs industry, based in Hong Kong, Hong Kong, with about 1,790 full-time employees.
It reported revenue of $548.51 million for fiscal year 2025, down 13.0% from fiscal year 2024, and net income of $456.91 million. Its largest business segment, Other Ventures, brought in 48% of segment revenue in fiscal year 2025; People's Republic of China was the largest region with 74%. Its market capitalization was $2.45 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally.
Hutchmed (China) reported $548.51 million in revenue for fiscal year 2025, down 13.0% from $630.20 million in fiscal year 2024.
Other Ventures, with $262.97 million or 48% of segment revenue in fiscal year 2025. Next: Oncology/Immunology - Marketed Products (39%) and Oncology/Immunology - R&D (13%).
People's Republic of China: 74% of revenue by region in fiscal year 2025, followed by U.S. and Others (26%).
$2.45 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Arcus Biosciences, Inc. (RCUS), Enliven Therapeutics, Inc. (ELVN), Zai Lab Limited (ZLAB), Immunome, Inc. (IMNM).